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In Western society, obesity is generally considered a primary risk for individuals with type 2 diabetes, since 60--90% of type 2 diabetic subjects are also obese ([@r1]). Initially, obese individuals have normal fasting glycemia with elevated plasma insulin, but become progressively more hyperglycemic and insulin resistant with a decline in plasma insulin levels associated with pancreatic β-cell dysfunction ([@r2]). Diabetic hyperglycemia results from a failure of insulin and elevated plasma glucose to increase glucose utilization and suppress endogenous glucose production ([@r2]). With \>90% of endogenous glucose production derived from liver ([@r3],[@r4]) and as much as 40% of alimentary glucose taken up by liver ([@r5]--[@r7]), for storage as glycogen ([@r8]--[@r10]), a progressive loss in these liver functions is associated with the deterioration of glycemic control and the eventual development of diabetes.

Whether liver uses or produces glucose is mostly determined by the activity of the first and last enzymes of hepatic glucose utilization and production, respectively. Net hepatic glucose flux is therefore the balance between the rate of glucose phosphorylation catalyzed by glucokinase (GK), the first step of hepatic glucose utilization, and the rate of glucose-6-phosphate (G-6-P) dephosphorylation catalyzed by glucose-6-phosphatase (G-6-Pase), the last step of hepatic glucose production. In studies of nondiabetic rats, glucose-induced suppression of net hepatic glucose production was associated with increased glucose phosphorylation ([@r11]) and GK activity was required for a rise in plasma glucose to suppress hepatic glucose production ([@r12]).

Male Zucker diabetic fatty (ZDF) rats are a widely used genetic model of obese type 2 diabetes, since many characteristic features of this model are common with human obese type 2 diabetes ([@r13]). Young ZDF rats exhibit normal fasting glycemia with slightly elevated plasma insulin levels and become progressively more hyperglycemic and insulin resistant as plasma insulin levels are decreased with pancreatic β-cell dysfunction ([@r14]). Previously, we reported that blunted hepatic glucose flux in response to a rise in plasma glucose and insulin, as seen in the early (10 weeks of age) and middle (14 weeks of age) phases of diabetes development in ZDF rats, is associated with impaired regulation of GK by GK regulatory protein (GKRP) ([@r15]--[@r17]). In our current study, we investigated GK expression in liver during the progressive development of diabetes in ZDF rats and examined what correlation altered GK expression may have with the development of defective hepatic glucose metabolism and hyperglycemia. We report here that GK expression in liver is progressively reduced with the development of hyperglycemia in ZDF rats and that normalizing liver GK expression restores plasma glucose to nearly normal levels by improving the responsiveness of hepatic glucose metabolism to alterations in blood glucose during this later phase of diabetes development in ZDF rats.

RESEARCH DESIGN AND METHODS
===========================

Animal and surgical procedures.
-------------------------------

Six-week-old male ZDF (ZDF/GmiCrl-*fa/fa*) rats and their lean littermates (ZDF/GmiCrl-+/*fa*) were purchased from Charles River Laboratories (Wilmington, MA) and were fed Formulab Diet 5008 (Purina Lab Diet; Purina Mills, Richmond, IN) in an environmentally controlled room with a 12-h light/dark cycle. In one group of studies, rats 7, 10, 14, or 20 weeks of age were fasted for 6 h (from 7:00 [a.m.]{.smallcaps} to 1:00 [p.m.]{.smallcaps}) and then anesthetized with sodium pentobarbital (60 mg/kg i.p.), and a laparotomy was performed. Blood samples were collected from the inferior mesenteric artery, and then the left lobe of the liver was frozen in situ using Wollenberg tongs precooled in liquid nitrogen. These sampling procedures took \<20 s from the point of successful anesthesia. In a second group of studies, surgery was performed to place sterile silicon rubber catheters in the ileal vein, the left common carotid artery, and the right external jugular vein at 17 weeks of age followed by a 2-week recovery period, as previously described ([@r15],[@r16],[@r18]). At 19 weeks of age, all animals received 15 mg/kg cyclosporine A via intraperitoneal injection the day before and on the day of adenovirus administration. Recombinant adenoviruses that contain a cDNA encoding rat liver GK (AdvCMV-GKL) or encoding a catalytically inactive mutant of GK (AdvCMV-mutGK) were prepared as described previously ([@r19],[@r20]) and administered into the hepatic portal vein via the ileal vein catheter at doses of 0.5 × 10^11^ (*n* = 4), 1 × 10^11^ (*n* = 5), or 2 × 10^11^ (*n* = 5) particles for AdvCMV-GKL and at 2 × 10^11^ particles for AdvCMV-mutGK (*n* = 4) or PBS (*n* = 4) in a final volume of 500 μl PBS. All experiments were conducted in accordance with the *Guide for the Care and Use of Laboratory Animals* of both the U.S. Department of Agriculture and the National Institutes of Health, with all protocols receiving approval from the Vanderbilt University Institutional Animal Care and Use Committee.

Experimental design of hyperglycemic clamp studies.
---------------------------------------------------

On the sixth day of the treatment with virus or vehicle, the rats were fasted for 6 h before each study, which consisted of a 2-h tracer equilibration period (−180 to −60 min), a 1-h basal period (−60 to 0 min), and a 3-h test period (0--180 min). At −180 min, a 60-μCi bolus of \[2-^3^H\]- and \[3-^3^H\]glucose was given through the jugular vein catheter and then infused continuously at 0.6 μCi/min. During the test period, the plasma glucose levels were kept at 400 mg/dl by infusing a 50% glucose solution into the systemic circulation through the jugular vein catheter at a variable rate. Blood samples were taken from the arterial catheter. Blood glucose levels were monitored using an Accu-Chek glucometer (Roche Diagnostics, Indianapolis, IN). At each sampling time, erythrocytes were resuspended in saline and given back to the test animal during the study. At the end of the experiment, the animal was anesthetized with an intravenous infusion of sodium pentobarbital (40 mg/kg) and a laparotomy was immediately performed. The left lobe of the liver was frozen in situ using Wollenberg tongs precooled in liquid nitrogen. This procedure took \<20 s from the point of successful anesthesia.

Western blot analysis for GK and GKRP.
--------------------------------------

Western blot analyses of GK and GKRP were performed with anti-rat GST-GK and GST-GKRP sera ([@r15],[@r16]).

Metabolites in blood and tissue.
--------------------------------

Glycogen and G-6-P content in liver, plasma glucose, plasma free fatty acids (FFAs), plasma triglyceride, plasma insulin, plasma glucagon, blood lactate, and blood alanine were determined as previously described ([@r15],[@r16]). \[2-^3^H\]- and \[3-^3^H\]glucose levels in plasma glucose and liver glycogen were determined by selective enzymatic detritiation of \[2-^3^H\]glucose ([@r16]). External standards of \[2-^3^H\]- and \[3-^3^H\]glucose suspended in control rat plasma were processed in parallel with each assay to calculate the degree of detritiation of each isotope during each sample assay. Overall completion of detritiation of \[2-^3^H\]glucose was 97.2 ± 0.4%, while 99.8 ± 0.3% of \[3-^3^H\]glucose remained intact. The specific activity of \[2-^3^H\]- and \[3-^3^H\]glucose (dpm/μmol) in plasma glucose was determined by the method of Debodo et al. ([@r21]).

Enzyme activities.
------------------

For GK and G-6-Pase activity measurements, 200 mg freeze-clamped livers were homogenized in 2 ml buffer containing 50 mmol/l HEPES, 100 mmol/l KCl, 1 mmol/l EDTA, 5 mmol/l MgCl~2~, and 2.5 mmol/l dithioerythritol ([@r22]). Homogenates were centrifuged at 100,000*g* for 45 min to sediment the microsomal fraction. GK and G-6-Pase activities were assayed in the postmicrosomal and the microsomal fractions, respectively, as described previously ([@r16]). Glycogen synthase and phosphorylase activities in the liver were measured using the method described by Golden et al. ([@r23]).

Calculations.
-------------

Rates of \[2-^3^H\]- and \[3-^3^H\]glucose--determined glucose turnover were calculated as the ratio of the rate of infusion of \[2-^3^H\]- and \[3-^3^H\]glucose (dpm · kg^−1^ · min^−1^) and the \[2-^3^H\]- and \[3-^3^H\] specific activity in plasma glucose, respectively, according to the steady-state equations of Steele et al. ([@r24]). Rate of endogenous glucose production was determined as the difference between \[3-^3^H\]glucose turnover rate and the glucose infusion rate. To estimate the amount of glucose incorporated into hepatic glycogen via the direct pathway, \[3-^3^H\] incorporated into glycogen was divided by the plasma glucose \[3-^3^H\] specific activity, respectively. Glucose cycling is defined as input of extracellular glucose into the G-6-P pool followed by the return of plasma glucose--derived G-6-P back into the extracellular pool; therefore, glucose cycling rate was calculated as the difference between \[2-^3^H\]glucose turnover rate and \[3-^3^H\]glucose turnover rate. The in vivo flux through G-6-Pase was calculated as the sum of endogenous glucose production plus glucose cycling.

Statistical analysis.
---------------------

The data collected are expressed as means ± SE. The significance of the differences between groups was analyzed by Student\'s *t* test. Differences were considered significant when *P* \< 0.05.

RESULTS
=======

Progression of diabetes and changes in hepatic GK protein and activity along with aging in ZDF rats.
----------------------------------------------------------------------------------------------------

As the ZCL rats aged, their BMI tended to increase along with an increase in body weight ([Fig. 1*A* and *B*](#f1){ref-type="fig"}). While plasma insulin and glucagon decreased and increased, respectively ([Fig. 1*C* and *D*](#f1){ref-type="fig"}), plasma glucose levels remained the same at all four age-groups ([Fig. 1*E*](#f1){ref-type="fig"}). In liver, protein levels of GK and GKRP ([Fig. 1*G* and *H*](#f1){ref-type="fig"}) as well as GK activity ([Fig. 1*F*](#f1){ref-type="fig"}) did not change. When these parameters were measured in ZDF rats and compared with those of ZCL rats, body weight, BMI, plasma insulin, plasma glucagon, and hepatic GK protein and activity were higher at 7 weeks of age, whereas plasma glucose and GKRP protein levels were similar ([Fig. 1](#f1){ref-type="fig"}). At 10 weeks of age, plasma glucose increased as hepatic GK activity declined ([Fig. 1*E* and *F*](#f1){ref-type="fig"}). After 10 weeks of age, plasma insulin and hepatic GK protein and activity progressively decreased as plasma glucose levels rose.

Effect of the treatment with AdvCMV-mutGK on hepatic GK activity and metabolic profiles.
----------------------------------------------------------------------------------------

Hepatic GK activity, metabolic profiles (plasma levels of glucose, insulin, glucagon, lipid, and gluconeogenic precursors), and hepatic glucose fluxes (glucose turnover, glucose cycling, endogenous glucose production, and G-6-Pase flux) in 20-week-old ZDF rats treated with AdvCMV-mutGK were similar to that of ZDF rats treated with vehicle, indicating that viral infection per se and expression of a catalytically inactive form of GK protein did not affect hepatic GK activity and metabolism.

Effect of the treatment with AdvCMV-GKL on hepatic GK activity, plasma glucose, and body weight.
------------------------------------------------------------------------------------------------

Treatment of ZDF rats with AdvCMV-GKL increased GK activity dose-dependently ([Fig. 2*A*](#f2){ref-type="fig"}). When ZDF rats were treated with AdvCMV-GKL at 1 or 2 × 10^11^ pfu, blood glucose levels gradually fell over a 4-day period and remained at this reduced level until the study was terminated on day 6 ([Fig. 2*B*](#f2){ref-type="fig"}). Body weight was not altered by this increased GK activity in liver ([Fig. 2*C* and *D*](#f2){ref-type="fig"}).

Metabolite profile of 20-week-old ZDF rats treated with AdvCMV-GKL before and during a hyperglycemic clamp.
-----------------------------------------------------------------------------------------------------------

[Figures 3](#f3){ref-type="fig"} and [4](#f4){ref-type="fig"} show a relationship between measured metabolic parameters and hepatic GK activity, as indicated by a smooth trend line for parameters measured before and during the clamp, respectively. The normal level of GK expression in a nondiabetic liver was determined by measuring GK activity in ZCL rats that underwent the same hyperglycemic clamp. The activity was determined to be 32.5 ± 3.2 mU/mg total protein (the activity range was from 28 to 40 mU/mg). ZDF rats treated with AdvCMV-GKL were divided into three groups for analytical comparison based on the level of hepatic GK activity (ZDF-L, lower than normal range, 4--18 mU/mg; ZDF-N, normal range, 21--55 mU/mg; ZDF-H, higher than normal range, 64--91 mU/mg) as determined at the end of the hyperglycemic clamp, and these groups were compared with a group of ZCL rats that also underwent the same hyperglycemic clamp. [Table 1](#t1){ref-type="table"} shows the summary of the metabolic profiles of these four groups of rats and statistical analyses of these metabolic parameters. Before a hyperglycemic clamp, compared with ZCL rats, ZDF-L rats had similar plasma insulin and glucagon levels and similar blood alanine levels. Plasma FFA level tends to be higher. Blood lactate and plasma triglyceride levels were much higher. Plasma glucose levels, \[2-^3^H\]glucose turnover rates (which represent G-6-Pase flux), \[3-^3^H\]glucose turnover rates, and glucose cycling rates were much higher. Plasma glucose levels were reduced and reached near-normal levels as hepatic GK activity approached that of ZCL rats, and the restoration of nearly normal plasma glucose levels were associated with decreased \[2-^3^H\]- and \[3-^3^H\]glucose turnover. Additionally, a further increase in GK activity to about twice that found in ZCL livers did not further decrease plasma glucose levels, but instead, tended to increase \[2-^3^H\]- and \[3-^3^H\]glucose turnover. While blood lactate levels were slightly increased, blood alanine levels, plasma insulin, plasma glucagon, and plasma triglycerides did not change.

In ZCL rats during a hyperglycemic clamp, when plasma glucose, insulin, and glucagon levels were raised to that seen in ZDF-L rats, levels of blood lactate, but not blood alanine and plasma triglyceride, tended to rise to that seen in ZDF rats. Glucose turnover rates were increased threefold, and endogenous glucose production was completely suppressed. Glucose cycling rates were also markedly increased, and G-6-Pase flux was not changed significantly. During a hyperglycemic clamp in ZDF-L rats, measured parameters were not changed from that of the basal period. In ZDF rats treated with AdvCMV-GKL, in parallel with increased GK activity in the liver, plasma insulin and glucagon were not changed from basal levels during the glucose clamp. Blood lactate, but not blood alanine and plasma triglyceride, levels were raised. Glucose turnover rates and glucose cycling rates increased. Additionally, endogenous glucose production was reduced with a decrease in G-6-Pase flux.

At the end of the clamp period, as compared with ZCL rats, in ZDF-L rats, G-6-P content ([Fig. 5*A*](#f5){ref-type="fig"}) was significantly lower and the amount of incorporated glucose into glycogen via the direct pathway was greatly reduced ([Fig. 5*C*](#f5){ref-type="fig"}). Glycogen phosphorylase a activity was significantly higher, and in contrast, glycogen synthase I activity was significantly lower ([Fig. 5*D--F*](#f5){ref-type="fig"}). In ZDF rats treated with AdvCMV-GKL, in parallel with increased GK activity, G-6-P content, glycogen content, and the amount of glucose incorporated into glycogen via the direct pathway were increased ([Fig. 5](#f5){ref-type="fig"} and [Table 1](#t1){ref-type="table"}). Total activity of glycogen synthase was not changed, but the active form of glycogen synthase was increased. Phosphorylase a activity was not changed. G-6-Pase activity ([Table 1](#t1){ref-type="table"}) and phosphoenolpyruvate carboxykinase protein expression (data not shown) were not significantly different between ZCL and ZDF rats without AdvCMV-GKL treatment and were not changed with increased GK expression in ZDF rats.

DISCUSSION
==========

Hepatic GK activity is decreased progressively with the development of hyperglycemia in ZDF rats, so that by 20 weeks of age, activity is only 30% of that found in nondiabetic ZCL rats. We demonstrated that normalization of hepatic GK activity in 20-week-old ZDF rats improves hepatic glucose flux at basal as well as when presented with a hyperglycemic challenge. The improved hepatic glucose flux restores blood glucose to normal levels. This demonstrates that altered hepatic glucose metabolism, responsible for hyperglycemia at this late stage of diabetes in this animal model, at least partly, resulted from decreased GK activity.

Hepatic GK expression decreases progressively during the development of diabetes in ZDF rats.
---------------------------------------------------------------------------------------------

An increase in GK activity in liver has been described in obese human subjects ([@r25]), obese hyperinsulinemic Zucker rats ([@r26]), and young obese *ob*/*ob* mice ([@r27]). In coincidence with these reports, ZDF rats have higher hepatic GK expression at 7 weeks of age when they are obese with euglycemia and hyperinsulinemia. GK expression then decreases progressively along with a progressive development of fasting hyperglycemia and a corresponding reduction of plasma insulin levels. It is known that expression of GK in the liver is regulated by insulin through phosphatidylinositol 3-kinase activation of a PKB/Akt-dependent signal ([@r28]). It was reported that the activation of PKB/Akt by phosphatidylinositol 3-kinase is impaired in the liver of ZDF rats ([@r29]). Therefore, a progressive decrease of GK expression during the development of diabetes may result from the presence of hepatic insulin resistance that becomes more evident when plasma insulin levels fall.

A role of GKRP in the regulation of not only GK activity but also protein levels in the liver may be an alternative explanation for the loss of GK activity with the progression of diabetes. In mice that do not express GKRP (GKRP gene ablated), GK resides in the cytoplasm, and its expression is decreased by 50% without a decrease in mRNA levels, which occurs despite the presence of normal plasma insulin and glucose levels ([@r30],[@r31]). In mice that express a mutant form of GK, which is localized to the cytoplasm and unable to bind GKRP, when compared with wild-type mice, it was found that expression of this GK was markedly lower despite being similar to wild-type levels of GK mRNA ([@r32]). Additionally, degradation of GK in cultured hepatocytes is decreased by increased GKRP expression ([@r33]). In ZDF rats, GK is predominantly localized in the nucleus with GKRP at an early stage of diabetes progression (7 and 10 weeks of age), which corresponds to a time when GK expression remains at normal levels ([@r15],[@r17]). However, at around 14 weeks of age, GK expression is markedly reduced, and GK is predominantly localized to the cytoplasm with the abnormal residency of GKRP in the cytoplasm ([@r16]). These data suggest the possibility that the inappropriate localization of GK in the cytoplasm may increase GK degradation and thus eventually result and/or contribute to lower GK levels.

Restoration of hepatic glucose flux responsiveness to changes in plasma glucose by normalization of hepatic GK expression.
--------------------------------------------------------------------------------------------------------------------------

Net hepatic glucose flux is the balance between glucose utilization as initiated by glucose phosphorylation to form G-6-P mediated by GK and glucose production as concluded by G-6-P dephosphorylation mediated by G-6-Pase. Therefore, a relative decrease in G-6-Pase flux and/or a relative increase in GK flux would lead to the observed decrease of net hepatic glucose production. The lack of suppression of endogenous glucose production in response to a hyperglycemic challenge in ZDF rats was associated with lower G-6-P content and glycogenesis via the direct pathway, suggesting lower glucose phosphorylation by GK. Normalization of GK expression restored suppression of endogenous glucose production in response to a rise in plasma glucose levels. The restoration was associated with restored glucose phosphorylation by GK, since hepatic G-6-P content, glucose cycling rate, and incorporation of glucose into glycogen via the direct pathway all increased. The restoration of glycogen synthesis by the direct pathway in response to a rise of plasma glucose was associated with a restored activation of glycogen synthase. It has been reported that increases in G-6-P through mass action and its allosteric regulatory effect on downstream enzymes in hepatocytes plays a major role in mediating the effects of GK overexpression on hepatic glucose metabolism, glycogen synthesis, and glycolysis ([@r34]).

Hepatic glucose production is predominantly via gluconeogenesis in ZDF rats ([@r16]). The rate of gluconeogenesis is controlled principally by the activities of several key enzymes, including G-6-Pase, fructose-1,6-bisphosphatase, and PEPCK. Increased G-6-Pase flux was observed in the liver of ZDF rats compared with ZCL rats. Interestingly, there was a significant decrease in G-6-Pase flux in parallel with normalized GK activity before and during a hyperglycemic clamp ([Table 1](#t1){ref-type="table"}). Under a hyperglycemic clamp, decreased G-6-Pase flux was observed despite increased content of G-6-P, a substrate of G-6-Pase, which suggests G-6-Pase activity was decreased. However, the *V*~max~ and apparent *K*~m~ of G-6-Pase activity, as measured in microsomal fractions of liver homogenates from ZDF rats, were not different from that of ZCL rats, and we detected no change in kinetic parameters after altering GK expression. Minassian et al. ([@r35]) reported a decreased *V*~max~ of G-6-Pase activity was observed after a short period of refeeding nondiabetic rats, as measured from homogenates of livers freeze-clamped in situ but not in the microsomal fractions isolated from these liver homogenates, which may suggest that an inhibitor that is either highly labile or that is lost during the process of microsome isolation ([@r35]). During the last decade, several intermediates of metabolism, such as free fatty acids, acyl-CoA, α-ketoglutarate ([@r36],[@r37]), and lipid products of phosphatidylinositol 3-kinase ([@r38]) have been reported to alter G-6-Pase activity allosterically. In a future study, we hope to identify what intracellular factor(s) may mediate the decreased G-6-Pase activity that is associated with the restoration of GK expression.

Relationship between increased glucose cycling and GK expression.
-----------------------------------------------------------------

ZDF rats have an increased rate of an apparent futile cycle of glucose to G-6-P and back to glucose that is a characteristic of insulin resistance and hyperglycemia seen with type 2 diabetes ([@r39]--[@r41]). This increased glucose cycling appears to be associated with increased rates of phosphorylation of glucose and/or dephosphorylation of G-6-P. Increased glucose phosphorylation increases the intracellular concentration of G-6-P and the fractional contribution of plasma glucose to this G-6-P pool. This also leads to an increased dephosphorylation of G-6-P derived from plasma glucose by increasing total G-6-Pase flux and/or the fraction of G-6-P derived from plasma glucose in the total G-6-P dephosphorylated by G-6-Pase (the later could occur even without an increase in total G-6-Pase flux).

It is unlikely that increased glucose cycling in ZDF rats is associated with only altered GK expression. Compared with ZCL rats, glucose cycling under a basal condition is threefold higher at an early stage of diabetes in ZDF rats (10 weeks of age), when these ZDF rats have similar GK expression, but do have lower GK activity due to a defective activation of the enzyme by glucose via an apparent failure of GK to dissociate from its inhibitory protein (GKRP) ([@r15],[@r17]). Glucose cycling is increased further during the progression of diabetes in ZDF rats, as is found at 20 weeks of age when GK expression is decreased ([Table 1](#t1){ref-type="table"}) ([@r15],[@r16]). However, the restoration and increase of GK expression at this phase of diabetes in ZDF rats did not affect glucose cycling. These findings suggest that other factors, other than lower GK activity, is involved in the increased glucose cycling associated with diabetes.

Maintenance of GK expression in liver as a possible gene therapy--based approach for reducing hyperglycemia in type 2 diabetes.
-------------------------------------------------------------------------------------------------------------------------------

O\'Doherty et al. ([@r42]) reported that lowering of blood glucose and plasma insulin by a sixfold increase in hepatic GK expression in nondiabetic rats using an adenovirus were accompanied by marked increases in plasma triglycerides, FFAs, cholesterol, β-hydroxybutylate, and lactate. Our study shows that increase in hepatic GK expression above normal tended to worsen hyperlipidemia and hyperlactemia in ZDF rats, a model of type 2 diabetes associated with obesity. We previously reported that \>90% of hepatic glucose production in ZDF rats is due to gluconeogenesis ([@r16]). Since elevated GK expression decreased endogenous glucose production under basal conditions and during hyperglycemic clamp, it is probable that the observed increase in blood lactate levels associated with greater GK expression resulted from an inhibition of gluconeogenesis. Increased glycolytic flux and/or decreased gluconeogenic flux, as a consequence of GK overexpression, would likely increase the concentration of substrates for de novo lipogenesis and esterification of triglyceride. Furthermore, excessively increased G-6-P concentration would stimulate expression of the fatty acid synthase gene via activation through its carbohydrate response element ([@r43],[@r44]). Therefore, an excessive induction of hepatic GK expression might have a risk to generate or worsen complications associated with type 2 diabetes.

On the other hand, O\'Doherty et al. ([@r42]) also reported that a mild (threefold) increase in hepatic GK expression in nondiabetic rats did not alter the basal metabolic profile. Transgenic mice overexpressing GK exhibited a slight decrease in blood glucose levels and no alteration of plasma lipid levels ([@r45]). These observations suggested a less impact of mildly increased hepatic GK expression on basal glycemia and lipidemia in normal animals. Nevertheless, transgenic mice expressing GK at approximately twofold of that in the wild-type mice are more tolerant to glucose challenge ([@r45]), more tolerant of streptozotocin-induced diabetes ([@r46]), and more resistant to high-fat diet--induced diabetes ([@r47],[@r48]). These benefits are not accompanied by altering plasma lactate, FFAs, and triglycerides ([@r46]--[@r48]). Our present study shows in 20-week-old ZDF rats that a short-term normalization of GK expression in liver improves hepatic glucose flux and restores blood glucose levels to near normal, even at the late stage of diabetes where plasma glucose levels are \>25 mmol/l and compensatory hyperinsulinemia does not exist anymore. It has been recently reported that single-dose administration of GK activator lowers fasting and postglucose--challenged plasma glucose levels by declining endogenous glucose production, in addition to by improving glucose utilization in patient with type 2 diabetes ([@r49]). These results clearly suggest that maintenance of near-normal GK activity in the liver, either by a gene therapy--based approach or possibly by pharmaceutical intervention, is a likely therapeutic target for the restoration of normoglycemia in type 2 diabetes.
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![Progressive changes in body weight (*A*), BMI (*B*), plasma insulin (*C*), plasma glucagon (*D*), plasma glucose (*E*), hepatic GK activity (*F*), hepatic GK protein (*G*), and hepatic GKRP protein (*H*) with aging in ZDF rats and ZCL rats. Rats were fasted from 6:00 [a.m.]{.smallcaps} for 6 h before sampling. Hepatic GK and GKRP protein are described as a ratio to that of a liver standard. ▪, ZDF rats. □, ZCL rats. \**P* \< 0.05 vs. lean littermates of the same age, with each group having five animals.](zdb0010955700001){#f1}

![Effect of AdvCMV-GKL treatments (dose range, 5--20 × 10^10^ pfu) on hepatic GK activity (*A*) and at a dose of 2 × 10^10^ pfu on blood glucose levels (*B*), body weight on the sixth day after adenovirus treatment (*C*), and difference in body weight between before treatment and sixth day after treatment with adenovirus (*D*). *A*: Values are means ± SE of 5--10 animals. *B*: Values are mean ± SE of 12 animals. *C* and *D*: black dots, ZDF rats treated with AdvCMV-GKL; gray dots, ZDF rats treated with AdvCMV-mutGK; light gray dots, ZDF rats treated with vehicle.](zdb0010955700002){#f2}

![Scatter plots with a smooth curve trend line to illustrate the relationship between GK activity and that of plasma glucose (*A*), plasma insulin (*B*), plasma glucagon (*C*), blood lactate (*D*), blood alanine (*E*), plasma triglycerides (*F*), glucose turnover rates determined with \[2-^3^H\]glucose (*G*) or \[3-^3^H\]glucose (*H*), and glucose cycling rates (*I*) for four groups of rats with different levels of GK activity in the liver. These groups are illustrated in the different panels as follows: black dots, ZDF rats treated with AdvCMV-GKL; gray dots, ZDF rats treated with AdvCMV-mutGK; light gray dots, ZDF rats treated with vehicle; white dots, ZCL rats. Each value is the average of samples obtained at three time points (−60, −30, and 0 min) during the control period before a hyperglycemic clamp.](zdb0010955700003){#f3}

![Scatter plots with a smooth curve trend line to illustrate the relationship between GK activity and that of plasma glucose (*A*), plasma insulin (*B*), plasma glucagon (*C*), blood lactate (*D*) blood alanine (*E*), plasma triglycerides (*F*), glucose infusion rates (*G*), glucose turnover rates determined with \[2-^3^H\]glucose (*H*) or \[3-^3^H\]glucose (*I*), endogenous glucose production rates (*J*), glucose cycling rates (*K*), and G-6-P flux rates (*L*) during a hyperglycemic clamp for four groups of rats with different levels of GK activity in the liver. These groups are illustrated in each of the different panels as follows: black dots, ZDF rats treated with AdvCMV-GKL; gray dots, ZDF rats treated with AdvCMV-mutGK; light gray dots, ZDF rats treated with vehicle; white dots, ZCL rats. Each value is the average of samples obtained at four time points (90, 120, 150, and 180 min) during the later half of a hyperglycemic clamp period.](zdb0010955700004){#f4}

![Scatter plots with a smooth curve trend line to illustrate the relationship in the liver between liver GK activity and that of G-6-P content (*A*), glycogen (*B*), glucose incorporated into glycogen via the direct pathway (*C*), the activity of glycogen phosphorylase (active form, *D*) and glycogen synthase (active form, *E*; active/total ratio, *F*) as determined at the end of a 3-h hyperglycemic clamp for four groups of rats with different levels of GK activity in the liver. These groups are illustrated in each of the different panels as follows: black dots, ZDF rats treated with AdvCMV-GKL; gray dots, ZDF rats treated with AdvCMV-mutGK; light gray dots, ZDF rats treated with vehicle; white dots, ZCL rats.](zdb0010955700005){#f5}

###### 

Hepatic glucose flux, plasma hormones, enzyme activities, and metabolites in 20-week-old ZCL and AdvCMV-GKL--treated ZDF rats, as measured before (basal) and during (clamp) a hyperglycemic clamp

                                                       Basal         Clamp                                                                                                                                                                                                                                                                                                                                                                                                           
  ---------------------------------------------------- ------------- ---------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------- ---------------------------------------------- -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  *n*                                                  5             8                                              7                                                                          7                                                                         5                                             8                                              7                                                                                                              7
  Body weight (g)                                      407 ± 16      366 ± 8[\*](#t1fn1){ref-type="table-fn"}       376 ± 6[\*](#t1fn1){ref-type="table-fn"}                                   372 ± 5[\*](#t1fn1){ref-type="table-fn"}                                                                                                                                                                                                                                              
  Plasma                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Glucose (mmol/l)                                     7.4 ± 0.3     23.9 ± 1.2[\*](#t1fn1){ref-type="table-fn"}    13.6 ± 0.9[\*](#t1fn1){ref-type="table-fn"}                                9.5 ± 0.4[\*](#t1fn1){ref-type="table-fn"}                                24.7 ± 0.9                                    27.4 ± 1.4                                     25.5 ± 2.0                                                                                                     28.0 ± 1.8
  Insulin (pmol/l)                                     291 ± 30      341 ± 20                                       324 ± 31                                                                   337 ± 40                                                                  360 ± 15                                      354 ± 27                                       365 ± 38                                                                                                       353 ± 59
  Glucagon (ng/l)                                      48 ± 3        44 ± 1                                         45 ± 3                                                                     48 ± 4                                                                    44 ± 2                                        40 ± 3                                         40 ± 3                                                                                                         46 ± 5
  FFAs (mmol/l)                                        0.78 ± 0.16   1.08 ± 0.24                                    1.05 ± 0.27                                                                0.99 ± 0.30                                                               0.70 ± 0.19                                   1.43 ± 0.24[\*](#t1fn1){ref-type="table-fn"}   1.54 ± 0.27[\*](#t1fn1){ref-type="table-fn"}                                                                   1.68 ± 0.28[\*](#t1fn1){ref-type="table-fn"}
  Triglyceride (mg/ml)                                 0.35 ± 0.11   4.44 ± 0.18[\*](#t1fn1){ref-type="table-fn"}   5.00 ± 0.62[\*](#t1fn1){ref-type="table-fn"}                               6.22 ± 0.76[\*](#t1fn1){ref-type="table-fn"}                              0.52 ± 0.14                                   5.24 ± 1.38[\*](#t1fn1){ref-type="table-fn"}   5.73 ± 1.00[\*](#t1fn1){ref-type="table-fn"}                                                                   7.25 ± 1.13[\*](#t1fn1){ref-type="table-fn"}
  Blood                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Lactate (mmol/l)                                     0.59 ± 0.09   1.92 ± 0.21[\*](#t1fn1){ref-type="table-fn"}   2.39 ± 0.26[\*](#t1fn1){ref-type="table-fn"}                               2.51 ± 0.21[\*](#t1fn1){ref-type="table-fn"}                              1.54 ± 0.29[‡](#t1fn3){ref-type="table-fn"}   2.16 ± 0.20[\*](#t1fn1){ref-type="table-fn"}   3.96 ± 0.58[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}[‡](#t1fn3){ref-type="table-fn"}   4.80 ± 0.48[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}[‡](#t1fn3){ref-type="table-fn"}
  Alanine (mmol/l)                                     1.91 ± 0.17   1.47 ± 0.15[\*](#t1fn1){ref-type="table-fn"}   1.55 ± 0.10[\*](#t1fn1){ref-type="table-fn"}                               1.48 ± 0.12[\*](#t1fn1){ref-type="table-fn"}                              1.90 ± 0.45                                   1.24 ± 0.13[\*](#t1fn1){ref-type="table-fn"}   1.70 ± 0.17                                                                                                    1.46 ± 0.15
  Rate                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
      Glucose turnover (μmol · kg^−1^ · min^−1^)       38 ± 3        80 ± 3[\*](#t1fn1){ref-type="table-fn"}        56 ± 2[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}    63 ± 4[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}   94 ± 6[‡](#t1fn3){ref-type="table-fn"}        98 ± 7                                         100 ± 8[‡](#t1fn3){ref-type="table-fn"}                                                                        132 ± 8[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}[‡](#t1fn3){ref-type="table-fn"}
      Glucose infusion (μmol · kg^−1^ · min^−1^)       0             0                                              0                                                                          0                                                                         111 ± 8                                       22 ± 10[\*](#t1fn1){ref-type="table-fn"}       88 ± 11[†](#t1fn2){ref-type="table-fn"}                                                                        143 ± 6[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}
      Glucose cycling (μmol · kg^−1^ · min^−1^)        18 ± 7        61 ± 5[\*](#t1fn1){ref-type="table-fn"}        56 ± 6[\*](#t1fn1){ref-type="table-fn"}                                    75 ± 9[\*](#t1fn1){ref-type="table-fn"}                                   53 ± 15[‡](#t1fn3){ref-type="table-fn"}       62 ± 5[\*](#t1fn1){ref-type="table-fn"}        82 ± 9[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}[‡](#t1fn3){ref-type="table-fn"}        90 ± 7[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}
      Glucose production (μmol · kg^−1^ · min^−1^)     38 ± 3        80 ± 3[\*](#t1fn1){ref-type="table-fn"}        56 ± 2[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}    63 ± 4[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}   −7 ± 4[‡](#t1fn3){ref-type="table-fn"}        80 ± 7[\*](#t1fn1){ref-type="table-fn"}        13 ± 11[†](#t1fn2){ref-type="table-fn"}[‡](#t1fn3){ref-type="table-fn"}                                        −9 ± 7[†](#t1fn2){ref-type="table-fn"}[‡](#t1fn3){ref-type="table-fn"}
      G-6-Pase flux (μmol · kg^−1^ · min^−1^)          58 ± 8        150 ± 11[\*](#t1fn1){ref-type="table-fn"}      110 ± 8[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}   133 ± 11[\*](#t1fn1){ref-type="table-fn"}                                 45 ± 6                                        142 ± 7[\*](#t1fn1){ref-type="table-fn"}       95 ± 13[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}                                       81 ± 10[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}[‡](#t1fn3){ref-type="table-fn"}
  Glucokinase activity                                                                                                                                                                                                                                                                                                                                                                                                                                                               
      Average (mU/mg protein)                                                                                                                                                                                                                                            32.5 ± 3.2                                    11.6 ± 1.9[\*](#t1fn1){ref-type="table-fn"}    34.5 ± 4.2[†](#t1fn2){ref-type="table-fn"}                                                                     77.8 ± 4.6[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}
      Range (mU/mg protein)                                                                                                                                                                                                                                              28--40                                        4--18                                          21--55                                                                                                         63--91
  G-6-Pase                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
      Activity (mU/mg protein)                                                                                                                                                                                                                                           777 ± 68                                      858 ± 53                                       805 ± 72                                                                                                       763 ± 59
      *K*~m~ for G-6-P (mmol/l)                                                                                                                                                                                                                                          2.49 ± 0.04                                   2.52 ± 0.04                                    2.51 ± 0.06                                                                                                    2.50 ± 0.05
  Glycogen phosphorylase a (units/g liver)                                                                                                                                                                                                                               16.1 ± 1.4                                    23.3 ± 2.7[\*](#t1fn1){ref-type="table-fn"}    20.1 ± 4.2                                                                                                     19.1 ± 3.1
  Glycogen synthase                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
      Total (units/g liver)                                                                                                                                                                                                                                              0.98 ± 0.04                                   0.89 ± 0.03                                    0.95 ± 0.01                                                                                                    0.88 ± 0.04
      Active form (units/g liver)                                                                                                                                                                                                                                        0.12 ± 0.03                                   0.06 ± 0.01[\*](#t1fn1){ref-type="table-fn"}   0.11 ± 0.03[†](#t1fn2){ref-type="table-fn"}                                                                    0.13 ± 0.02[†](#t1fn2){ref-type="table-fn"}
      % Active                                                                                                                                                                                                                                                           12.3 ± 3.7                                    6.6 ± 0.9[\*](#t1fn1){ref-type="table-fn"}     11.5 ± 2.6                                                                                                     14.5 ± 1.6
  Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
      G-6-P (nmol/g liver)                                                                                                                                                                                                                                               203 ± 39                                      118 ± 8[\*](#t1fn1){ref-type="table-fn"}       242 ± 23[†](#t1fn2){ref-type="table-fn"}                                                                       395 ± 42[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}
      Glycogen (μmol glucose/g liver)                                                                                                                                                                                                                                    184 ± 33                                      249 ± 27                                       381 ± 63[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}                                      475 ± 52[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}
      Glycogen--new synthesis (μmol glucose/g liver)                                                                                                                                                                                                                     43 ± 3                                        15 ± 5[\*](#t1fn1){ref-type="table-fn"}        47 ± 7[†](#t1fn2){ref-type="table-fn"}                                                                         68 ± 6[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}

ZDF rats were divided into three groups based on the level of hepatic GK activity achieved by AdvCMV-GKL treatment relative to ZCL rats (ZDF-L, \<ZCL; ZDL-N, =ZCL; ZDF-H, \>ZCL). Significant differences (*P* \< 0.05) from the corresponding values of the

ZCL group, from the

ZDF-L group, and from

basal values within the same group are indicated.

[^1]: Corresponding author: Masakazu Shiota, <masakazu.shiota@vanderbilt.edu>
